Moreover, the 36-month beta value for JAGX is 0.86. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JAGX is 8.06M and currently, short sellers hold a 8.40% of that float. On December 27, 2024, JAGX’s average trading volume was 378.70K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
JAGX) stock’s latest price update
Jaguar Health Inc (NASDAQ: JAGX)’s stock price has dropped by -3.30 in relation to previous closing price of 1.06. Nevertheless, the company has seen a gain of 17.40% in its stock price over the last five trading days. accesswire.com reported 2024-12-19 that Magdalena to explore coca leaf’s possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of Peru Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / December 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Magdalena Biosciences, Inc. (“Magdalena”), a joint venture formed by Jaguar and Filament Health Corp. (OTCQB:FLHLF)(Cboe CA:FH)(FSE:7QS) (“Filament” or “Filament Health”), successfully completed an import of six kilograms of coca leaf from Peru to Filament’s Metro Vancouver research and development facility.
JAGX’s Market Performance
JAGX’s stock has risen by 17.40% in the past week, with a monthly rise of 2.50% and a quarterly drop of -14.58%. The volatility ratio for the week is 8.69% while the volatility levels for the last 30 days are 9.28% for Jaguar Health Inc. The simple moving average for the past 20 days is 3.40% for JAGX’s stock, with a -72.91% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -0.34% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.25% of loss for the given period.
Volatility was left at 9.28%, however, over the last 30 days, the volatility rate increased by 8.69%, as shares surge +2.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.07% lower at present.
During the last 5 trading sessions, JAGX rose by +16.83%, which changed the moving average for the period of 200-days by -76.29% in comparison to the 20-day moving average, which settled at $0.9910. In addition, Jaguar Health Inc saw -88.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.85 for the present operating margin
- 0.69 for the gross margin
The net margin for Jaguar Health Inc stands at -3.6. The total capital return value is set at -0.77. Equity return is now at value -432.40, with -72.69 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 2.44. The interest coverage ratio of the stock is -34.76.
Currently, EBITDA for the company is -33.13 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 3.15. The receivables turnover for the company is 8.02for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.84.
Conclusion
To wrap up, the performance of Jaguar Health Inc (JAGX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
